糖尿病酮症酸中毒 中国就医指南

Diabetic ketoacidosis (DKA) is a life-threatening acute metabolic complication of diabetes mellitus, predominantly occurring in type 1 diabetes but increasingly recognized in insulin-deficient type 2 diabetes—particularly among individuals of African, Hispanic, or Asian descent. It is characterized by the triad of hyperglycemia (blood glucose >250 mg/dL), metabolic acidosis (arterial pH <7.3 or serum bicarbonate <18 mmol/L), and ketonemia/ketonuria due to severe insulin deficiency and counterregulatory hormone excess (e.g., glucagon, cortisol, catecholamines). Pathogenically, absolute or relative insulin deficiency impairs glucose uptake in muscle and adipose tissue while simultaneously promoting lipolysis and hepatic ketogenesis. Unchecked, this leads to accumulation of acetoacetate, beta-hydroxybutyrate, and acetone—causing osmotic diuresis, profound dehydration, electrolyte derangements (especially potassium, sodium, phosphate), and systemic acidosis. DKA can be precipitated by infection (e.g., pneumonia, UTI), myocardial infarction, stroke, non-adherence to insulin therapy, new-onset diabetes, or use of SGLT2 inhibitors. Epidemiologically, DKA accounts for ~4–8% of all diabetes-related hospitalizations globally; incidence in high-income countries ranges from 1–5 episodes per 1,000 person-years among people with type 1 diabetes. In China, hospitalization rates are rising—driven by delayed diagnosis, limited access to continuous glucose monitoring, and socioeconomic barriers to insulin access. Key risk factors include younger age (<19 years), low socioeconomic status, psychiatric comorbidities (e.g., depression, eating disorders), prior DKA episodes, and lack of structured diabetes education. Untreated or poorly managed DKA carries mortality rates of 1–5% in modern tertiary centers—but rises sharply (>10%) in elderly patients or those with comorbidities like renal failure or sepsis. Beyond acute mortality, recurrent DKA significantly erodes quality of life: patients report chronic fatigue, cognitive fog, anxiety around insulin dosing, fear of hospitalization, disrupted work/school attendance, and strained family dynamics. Long-term consequences include microvascular complications acceleration, increased cardiovascular risk, and reduced health-related quality of life scores (measured by SF-36 or ADDQoL). Early recognition of symptoms—including polyuria, polydipsia, nausea/vomiting, abdominal pain, Kussmaul respirations, fruity breath odor, confusion, or altered mental status—is critical. Prompt emergency intervention—fluid resuscitation, intravenous insulin infusion, careful electrolyte replacement (especially potassium), and identification/treatment of precipitating causes—remains the cornerstone of management. Multidisciplinary follow-up involving endocrinologists, certified diabetes care and education specialists (CDCES), and behavioral health providers is essential to prevent recurrence and optimize long-term outcomes.

# 糖尿病酮症酸中毒（DKA）治疗方案与费用明细（内分泌科）

一、非手术/保守治疗（一线标准方案）

适用于绝大多数初发或轻中度DKA患者（pH≥7.0，意识清醒，无休克）：

• •核心治疗：静脉胰岛素持续泵入（0.1 U/kg/h起始）、生理盐水补液（首2h 1000–2000 mL）、电解质纠正（氯化钾5–10 g/d，依血钾动态调整）
• •必需检查费：血气分析（80–120元）、血糖/β-羟丁酸（60–90元）、电解质+肾功能（120–180元）、尿酮体（25–40元）、心电图（50–80元）
• •总费用区间：

- ICU监护（需呼吸支持或昏迷者，2–4天）：12,800–26,000元

二、手术/介入方案

DKA为内科急症，无手术或微创根治性操作。所有治疗均属内分泌科规范抢救范畴，不涉及外科干预。

三、复杂/并发症/晚期方案

• •合并严重感染（如脓毒症）：加用广谱抗生素（头孢哌酮舒巴坦等），费用增加3,000–9,500元
• •急性肾损伤需CRRT：单次治疗费4,500–6,800元，日均12,000–18,000元
• •脑水肿抢救（甘露醇+高渗盐水+ICP监测）：额外增加5,200–11,000元

四、方案快速选择指南

• •预算有限/轻症（pH>7.2，无呕吐昏迷）：选普通病房保守治疗（≈5,000元）
• •中重度（pH<7.1、意识模糊、收缩压<90mmHg）：必须ICU监护（≈18,000元起）
• •合并脓毒症或AKI：立即启动多学科协作，预估总费用≥25,000元